Page 141 - 2021_06-Haematologica-web

InHIBIT-Bleed: bevacizumab for bleeding in HHT
References
1.Fuchizaki U, Miyamori H, Kitagawa S, Kaneko S, Kobayashi K. Hereditary haemor- rhagic telangiectasia (Rendu-Osler-Weber disease). Lancet. 2003;362(9394):1490-1494.
2. Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diag- nosis and management from the hematolo- gist's perspective. Haematologica. 2018;103 (9):1433-1443.
3. Kwaan HC, Silverman S. Fibrinolytic activi- ty in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol. 1973;107(4): 571-573.
4. Watanabe M, Hanawa S, Morishima T. Fibrinolytic activity in cutaneous lesions of hereditary hemorrhagic telangiectasia. Nihon Hifuka Gakkai Zasshi.1985;95(1):11.
5. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24(6):203- 219.
6. Letteboer TG, Mager HJ, Snijder RJ, et al. Genotype-phenotype relationship for local- ization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A. 2008;146A(21):2733- 2739.
7. Abdalla SA, Geisthoff UW, Bonneau D, et al. Visceral manifestations in hereditary haem- orrhagic telangiectasia type 2. J Med Genet. 2003;40(7):494-502.
8. Kasthuri RS, Montifar M, Nelson J, et al. Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol. 2017 Jun 22. [Epub ahead of print]
9. OS AA, Friedman CM, White RI Jr. The nat- ural history of epistaxis in hereditary hemor- rhagic telangiectasia. Laryngoscope. 1991; 101(9):977-980.
10. Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW. Complications and mortality in hereditary hemorrhagic telangiectasia: a population-based study. Neurology. 2015;84(18):1886-1893.
11. Kjeldsen AD, Vase P, Green A. [Hereditary hemorrhagic telangiectasia. A population- based study on prevalence and mortality among Danish HHT patients]. Ugeskr Laeger. 2000;162(25):3597-3601.
12. Gaillard S, Dupuis-Girod S, Boutitie F, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9): 1494-1502.
13. Ingrosso M, Sabba C, Pisani A, et al. Evidence of small-bowel involvement in hereditary hemorrhagic telangiectasia: a capsule-endoscopic study. Endoscopy. 2004;36(12):1074-1079.
14. Iyer VN, Brinjikji W, Apala D, et al. Impact of age on outcomes in hospitalized patients with hereditary hemorrhagic telangiectasia. Adv Hematol. 2018;2018:4798425.
15. Brinjikji W, Wood CP, Lanzino G, et al. High rates of bleeding complications among hos-
pitalized patients with hereditary hemor- rhagic telangiectasia in the United States. Ann Am Thorac Soc. 2016;13(9):1505-1511.
16.Letarte M, McDonald ML, Li C, et al. Reduced endothelial secretion and plasma levels of transforming growth factor-beta1 in patients with hereditary hemorrhagic telangiectasia type 1. Cardiovasc Res. 2005;68(1):155-164.
17. Cirulli A, Liso A, D'Ovidio F, et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemor- rhagic telangiectasia. Acta Haematol. 2003;110(1):29-32.
18. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluo- rouracil, and leucovorin for metastatic col- orectal cancer. N Engl J Med. 2004;350(23):2335-2342.
19. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovas- cular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035-1047.
20. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009;360(20):2143-2144.
21. Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009;361 (9):931; author reply 931-932.
22. Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2011;364(7):688-689.
23. Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med. 2019;285(2):223-231.
24. Al-Samkari H. Systemic bevacizumab for hereditary hemorrhagic telangiectasia: con- siderations from observational studies. Otolaryngol Head Neck Surg. 2019;160(2): 368.
25. Iyer VN, Apala DR, Pannu BS, et al. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-relat- ed epistaxis and gastrointestinal bleeding. Mayo Clin Proc. 2018;93(2):155-166.
26. Guilhem A, Fargeton AE, Simon AC, et al. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retro- spective study of 46 patients. PLoS One. 2017;12(11):e0188943.
27. Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiec- tasia associated with bleeding. Am J Hematol. 2016;91(6):E313-314.
28. Epperla N, Kleman A, Karafin M, Foy P. Re- treatment versus extended treatment strate- gy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better? Ann Hematol. 2018;97(9):1727-1729.
29. Yin LX, Reh DD, Hoag JB, et al. The mini- mal important difference of the epistaxis
severity score in hereditary hemorrhagic telangiectasia. Laryngoscope. 2016;126(5): 1029-1032.
30. Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen C. Medical treatment for epistaxis in hered- itary hemorrhagic telangiectasia: a meta- analysis. Otolaryngol Head Neck Surg. 2018;160(1):22-35.
31. Geisthoff UW, Seyfert UT, Kubler M, Bieg B, Plinkert PK, Konig J. Treatment of epis- taxis in hereditary hemorrhagic telangiecta- sia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014;134(3):565-571.
32. Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial. Acta Med Scand. 1981;209(5):393-396.
33. Whitehead KJ, Sautter NB, McWilliams JP, et al. Effect of topical intranasal therapy on epis- taxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA. 2016;316(9):943-951.
34. Dupuis-Girod S, Pitiot V, Bergerot C, et al. Efficacy of TIMOLOL nasal spray as a treat- ment for epistaxis in hereditary hemorrhag- ic telangiectasia. A double-blind, random- ized, placebo-controlled trial. Sci Rep. 2019;9(1):11986.
35. Dupuis-Girod S, Ambrun A, Decullier E, et al. Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial. JAMA. 2016;316(9):934-942.
36. Samour M, Saygin C, Abdallah R, Kundu S, McCrae KR. Pomalidomide in hereditary hemorrhagic telangiectasia: interim results of a phase I study. Blood. 2016;128(22):210.
37. Faughnan ME, Gossage JR, Chakinala MM, et al. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis. 2019;22(1):145-155.
38. Parambil JG, Woodard TD, Koc ON. Pazopanib effective for bevacizumab-unre- sponsive epistaxis in hereditary hemorrhag- ic telangiectasia. Laryngoscope. 2018;128 (10):2234-2236.
39. Buscarini E, Botella LM, Geisthoff U, et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019;14(1):28.
40. Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307(9):948-955.
41. Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN. An international sur- vey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Haemophilia. 2020;26(6): 1038-1045.
42. Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. Orphanet J Rare Dis. 2019;14(1):256.
haematologica | 2021; 106(8)
2169